Esperion Therapeutics (ESPR) Misses Q1 EPS by 5c
Tweet
Share
E-mail
Get Alerts ESPR Hot Sheet
Join SI Premium – FREE
Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.21), $0.05 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $64.99 million versus the consensus estimate of $50.64 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Doncasters (DPC) indicating open around $40, IPO priced at $33
- Omnicom and NBCUniversal develop CTV ad tool with AI optimization
- Saia launches REV initiative with 2,000+ transit time improvements
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
